Markets:

Overview

News

Currencies

International

Treasuries

Cerevel Therapeutics Holdings, Inc. - Common Stock (NQ:CERE)

44.96 UNCHANGED

Last Price Updated: 4:15 PM EDT, Jul 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cerevel Therapeutics Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Tuesday Talk: Big-Tech Under Attack ↗

March 26, 2024

On Thursday the Justice Dept. filed an antitrust suit against Apple. The suit joins two others already filed against Google. How much this will affect the market in the long run is up for grabs.

Via Talk Markets

Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? ↗

March 25, 2024

AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease.

Via Benzinga

3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 ↗

March 09, 2024

Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market.

Via InvestorPlace

Is AbbVie Stock a Buy Now? ↗

February 22, 2024

Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable.

Via The Motley Fool

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space ↗

February 16, 2024

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset...

Via Benzinga

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst ↗

February 06, 2024

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy.

Via Benzinga

AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall ↗

February 02, 2024

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products.

Via Benzinga

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures ↗

January 29, 2024

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp (Nasdaq – MGRC), Science 37 Holdings, Inc. (Nasdaq – SNCE), Eagle Bulk Shipping Inc. (NYSE - EGLE), Cerevel Therapeutics Holdings, Inc. (Nasdaq –

January 29, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

ABBV: This Top Biotech Just Went On A Buying Spree ↗

January 25, 2024

AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel).

Via Talk Markets

7 Dividend Aristocrats That Will Pay You for Years to Come ↗

January 22, 2024

If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024.

Via InvestorPlace

CERE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Cerevel Therapeutics Holdings, Inc. Is Fair to Shareholders

January 08, 2024

From Halper Sadeh LLC

Via Business Wire

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

Is AbbVie Stock a Buy Now? ↗

January 07, 2024

The company is grappling with losing Humira's patent protection in 2023.

Via The Motley Fool

Topics Intellectual Property

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Icosavax, Inc. (Nasdaq - ICVX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

January 04, 2024

From Brodsky & Smith LLC

Via GlobeNewswire

Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 ↗

December 29, 2023

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.

Via Benzinga

JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know ↗

December 28, 2023

Via Benzinga

December 26, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Tesla To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday ↗

December 22, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alteryx, Inc. (NYSE – AYX), Rain Oncology, Inc. (Nasdaq – RAIN), Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc.

December 18, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

The 7 Most Undervalued Growth Stocks to Buy in December ↗

December 13, 2023

Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback.

Via InvestorPlace

AbbVie continues shopping spree with biotech buyout

December 12, 2023

While the diversifying AbbVie appears to be in a state of flux, there is one constant investors can depend on — the dividend.

Via MarketBeat

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq - CNSL), Cerevel Therapeutics Holdings, Inc. (Nasdaq – CERE), ImmunoGen, Inc. (Nasdaq – IMGN), Graphite Bio, Inc.

December 11, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 11, 2023

Via Benzinga

The 3 Best Cheap Stocks to Buy in December ↗

December 10, 2023

Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately.

Via InvestorPlace

4 Top Dividend Stocks Yielding More Than 4% to Buy Hand-Over-Fist This December ↗

December 10, 2023

These companies offer above-average income streams that should continue rising.

Via The Motley Fool

AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? ↗

December 10, 2023

The big drugmaker went on a holiday shopping spree.

Via The Motley Fool

CEREVEL THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cerevel Therapeutics - CERE

December 08, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next? ↗

December 08, 2023

Here's what's attracting lucrative buyout offers from big pharmaceutical companies these days.

Via The Motley Fool

AbbVie's New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Analyst Signals ↗

December 07, 2023

Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value of approximately $8.7 billion, or $45 per share in cash, with the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.